MAGEA1 and breast carcinoma: Recently, MAGE-A1, MAGE-A, and NY-ESO-1 protein expression was reported only in 33% (16/49), 33% (16/49), and 22% (11/49) of breast cancer patients, respectively by IHC analysis [32].